Form 4: Bluebird Bio CFO Acquires 300,000 Stock Options
SEC Form 4 Filing
Bluebird Bio's Chief Financial Officer, O. James Sterling, acquired 300,000 stock options on July 1, 2024, according to a Form 4 filing.
Summary
- O. James Sterling, the Chief Financial Officer of bluebird bio, Inc., acquired 300,000 stock options on July 1, 2024.
- The options have an exercise price of $0.98.
- The options vest over a four-year period, with 25% vesting on July 1, 2025, and the remainder vesting in equal monthly installments over the following 36 months.
- The options expire on July 1, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, so the sentiment is neutral.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. This filing indicates the CFO's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by the CFO could be viewed positively by shareholders as it aligns the CFO's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: CFO acquired 300,000 stock options. |
| 07/01/2025 | 25% of the stock options vest. |
| 07/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.